熱門資訊> 正文
NeuroBo Pharmaceuticals GAAP每股收益为-1.85美元
2024-08-15 23:57
- NeuroBo Pharmaceuticals press release (NASDAQ:NRBO): Q2 GAAP EPS of -$1.85.
- Cash was approximately $27.9 million as of June 30, 2024, compared to approximately $22.4 million as of December 31, 2023.
More on NeuroBo Pharmaceuticals
- NeuroBo Pharmaceuticals signs exclusive license agreement with Mthera Pharma
- NeuroBo Pharma prices private placement and direct offering to raise up to $70M
- Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals
- Historical earnings data for NeuroBo Pharmaceuticals
- Financial information for NeuroBo Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
